Literature DB >> 23800140

Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers.

Yun-Hao Xun1, Guo-Qing Zang, Jian-Chun Guo, Xiu-Li Yu, Hong Liu, Jing Xiang, Jing Liu, Jun-Ping Shi.   

Abstract

BACKGROUND AND AIMS: The role of serum quantitative hepatitis B surface antigen (qHBsAg) in identifying hepatitis B virus (HBV) carriers with significant fibrosis is unknown. This study aims to evaluate the diagnostic value of qHBsAg for hepatic fibrosis in hepatitis B e antigen (HBeAg)-positive HBV carriers.
METHODS: Consecutive biopsy-proven HBeAg-positive HBV carriers were prospectively recruited in our center from 2009 to 2011 and were randomly divided into training and validation set. Area under receiver-operator curve (AUC) was used to determine the diagnostic accuracy of simple tests for significant fibrosis (Scheuer stage, F ≥ 2).
RESULTS: Overall, a total of 197 eligible patients (median age 31 years; 149 males) were enrolled. The median qHBsAg was 4.20 (log10 IU/mL). Significant fibrosis was confirmed in 112 (56.9%) patients. By logistical regression analysis, qHBsAg and γ-glutamyl transpeptidase were identified as predictors for significant fibrosis in training set (n = 124). Thus, qHBsAg index and γ-glutamyl transpeptidase to qHBsAg ratio (GqHBsR) were selected for the subsequent analysis. In the training set, an AUC of 0.762, 0.826, 0.749, and 0.771 was observed for qHBsAg index, GqHBsR, FIB-4, and aspartate aminotransferase to platelet ratio index, respectively (all P < 0.05). GqHBsR yielded a higher AUC than aspartate aminotransferase to platelet ratio index and FIB-4 (both P < 0.05). Using the optimal cut-off of 7.78, GqHBsR showed a sensitivity of 78.9% and a specificity of 73.6%. About 80% of liver biopsy could be avoided in the entire cohort.
CONCLUSIONS: Serum qHBsAg-based simple tests, especially GqHBsR, can accurately and specifically identify significant fibrosis in treatment-naïve HBeAg-positive HBV carriers.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  HBeAg positive; chronic HBV carriers; non-invasive diagnosis; quantitative HBsAg; significant fibrosis

Mesh:

Substances:

Year:  2013        PMID: 23800140     DOI: 10.1111/jgh.12304

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  11 in total

1.  Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Authors:  Lin-Yan Zeng; Jiang-Shan Lian; Jian-Yang Chen; Hong-Yu Jia; Yi-Min Zhang; Dai-Rong Xiang; Liang Yu; Jian-Hua Hu; Ying-Feng Lu; Lin Zheng; Lan-Juan Li; Yi-Da Yang
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 2.  Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B.

Authors:  Lung-Yi Mak; Wai-Kay Seto; James Fung; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2019-11-19       Impact factor: 6.047

3.  Diagnostic value of FIB-4 for liver fibrosis in patients with hepatitis B: a meta-analysis of diagnostic test.

Authors:  Zhi Yin; Jin Zou; Qiongxuan Li; Lizhang Chen
Journal:  Oncotarget       Date:  2017-04-04

4.  Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection.

Authors:  Louise O Downs; David A Smith; Sheila F Lumley; Meha Patel; Anna L McNaughton; Jolynne Mokaya; M Azim Ansari; Hizni Salih; Kinga A Várnai; Oliver Freeman; Sarah Cripps; Jane Phillips; Jane Collier; Kerrie Woods; Keith Channon; Jim Davies; Eleanor Barnes; Katie Jeffery; Philippa C Matthews
Journal:  mBio       Date:  2019-06-25       Impact factor: 7.867

5.  Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients.

Authors:  Bengü Tatar; Ayse Acar; Pelın Adar; Sukran Kose
Journal:  Clin Exp Hepatol       Date:  2020-02-17

6.  The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen -positive and -negative chronic hepatitis B patients.

Authors:  Lei Tan; Shi-Lei Xu; Zhi-Shuo Mo; Jian-Rong Liu; Wei-Qiang Gan; Jie-Huan Chen; Zhi-Liang Gao; Ze-Qian Wu
Journal:  Ann Transl Med       Date:  2021-09

7.  Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China.

Authors:  Wen Jia; Xun Qi; Yan-Yan Ji; Yun-Hao Xun; Hong Wang; Wen-Hong Zhang; Jian-Hua Yang; Jin-Yu Wang; Hao-Xiang Zhu; Ri-Cheng Mao; Ji-Ming Zhang
Journal:  Hepat Mon       Date:  2015-08-30       Impact factor: 0.660

8.  Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients.

Authors:  Mei-Zhu Hong; Wen-Qi Huang; Feng Min; Jin-Chao Xu; Zhen Lin; Kuang-Nan Fang; Jin-Shui Pan
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

9.  The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis.

Authors:  Yuanyuan Li; Yu Chen; Ying Zhao
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

10.  Serum hepatitis B surface antigen levels predict insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with normal or mildly elevated alanine transaminase levels.

Authors:  Qiang Li; Weixia Li; Chuan Lu; Yuxian Huang; Liang Chen
Journal:  Oncotarget       Date:  2017-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.